Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia

Complete title: A Phase 1 Study of SGN-CD123A in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Research Study Number 9653
 
Principal Investigator Roland Walter, MD
 
Phase I

Research Study Description

The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 9653
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia; Leukemia, Myeloid; Immunotherapy

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials